Pharmaceutical industries have received much interest in 
pharmaceutical research in the area of oral drug delivery. 
Oral administration of drug is the most convenient and 
versatile way due to the simple and comfortable use and 
flexibility concerning dose strength, and type of 
formulation. GRDDS is an approach to prolong gastric 
residence time, thereby targeting site-specific drug release 
in upper GI tract improving the oral sustained delivery of 
drug that have an absorption window in a particular region 
of the GI tract. These systems help in continuously releasing 
the drug before it reaches the absorption window, thus 
ensuring optimal bioavailability. This manner may increase 
patient compliance and provides continuously controlled 
release administration of sparingly soluble drugs at the 
particular sites of absorption. More than 55% of drug 
available in the commercial market used for orally. During 
the last five decades, little oral delivery has been produced 
to 
act as a drug reservoir from which the active 
ingredients are specified period of time released and at 
controlled the release rate. Method for preparing GRDDS is 
simple and straight forward, and as a result economically 
attractive. An assortment of approaches for gastric retention 
are floating, non-floating, swelling, bioadhesive, magnetic 
controlled, and dual working systems etc This patent overview summarizes the recent marketed 
approach, patents scenario and future aspect of the 
GRDDS. This patent outline is also provides 
the information of oral GRDDS intended for its 
application.